Off-Label and Off-NCCN Guidelines Uses of Antineoplastic Drugs in China
- PMID: 23802104
- PMCID: PMC3684455
Off-Label and Off-NCCN Guidelines Uses of Antineoplastic Drugs in China
Abstract
Background: To evaluate off-label and off-NCCN guidelines uses of antineoplastic drugs in a major Chinese hospital.
Methods: Totally 1122 patients were selected from July to December 2011. Then, the off-label and off-NCCN guidelines uses of antineoplastic drugs were analyzed.
Results: In 798 of 1122 patients (71.12%), drugs were used for off-label. In 317 of 1122 patients (28.25%), the drugs were prescribed for off-label and off-NCCN guidelines. 2591 medical orders for 1122 patients, 1051/2591 (40.56%) medical orders were off-label; 445/2591(17.17%) medical orders were off-label and off-NCCN guidelines. In 445 off-label and off-NCCN medical orders, 399 (89.66%) were unapproved indications, 38 (8.54%) were unapproved drug concentration and 12 (2.70%) were unapproved route of administration. Percentage of off-label and off-NCCN guidelines drug uses in male was higher than that in female (21.92% vs. 11.39%, P<0.01). Compared with other lines of treatment, percentage of off-label and off-NCCN guidelines drug uses in postoperative adjuvant was the smallest (P<0.01) and percentage in three or multi-line treatments was the highest (P<0.01). The pancreatic cancer possessed the highest percentage (38.74%) of off-label and off-NCCN guidelines drug uses among all types of cancer (P<0.01).
Conclusion: Off-label uses of antineoplastic drugs are generally common in China hospitals based on NCCN guidelines. The fact suggests that anti-tumor treatment was relatively standard in China. Off-label and off-NCCN guidelines drug uses were mainly for individual treatment. Doctors should fully consider the adverse drug reaction, contraindication, cautions and increase the drug security monitoring. Uncorrected drug concentration should be avoided for drug risk.
Keywords: Antineoplastic drug use; China; Off-label and off-NCCN guidelines.
Similar articles
-
National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study.Cancer Treat Rev. 2020 Dec;91:102113. doi: 10.1016/j.ctrv.2020.102113. Epub 2020 Oct 20. Cancer Treat Rev. 2020. PMID: 33128993 Review.
-
Improving Good Practice: A Survey of Unlicensed and Off-Label Drug Use in a General Hospital in China.Ther Innov Regul Sci. 2013 Jul;47(4):397-404. doi: 10.1177/2168479013491753. Ther Innov Regul Sci. 2013. PMID: 30235519
-
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals.Ann Oncol. 2019 Oct 1;30(10):1647-1652. doi: 10.1093/annonc/mdz232. Ann Oncol. 2019. PMID: 31373348 Free PMC article.
-
[Analysis on off-label use of drugs in pediatric guidelines and consensus published by Chinese authors].Zhonghua Er Ke Za Zhi. 2022 Mar 2;60(3):215-220. doi: 10.3760/cma.j.cn112140-20210923-00813. Zhonghua Er Ke Za Zhi. 2022. PMID: 35240741 Chinese.
-
Retrospective analysis of off-label medication use at a plastic surgery hospital in China and evidence-based evaluation.Dermatol Ther. 2021 Jan;34(1):e14424. doi: 10.1111/dth.14424. Epub 2020 Oct 29. Dermatol Ther. 2021. PMID: 33070423 Review.
Cited by
-
Developing CSCO Lung Cancer Practice Guidelines Stratified by Resource Availability and Treatment Value.J Glob Oncol. 2016 Oct 12;3(4):285-288. doi: 10.1200/JGO.2016.006734. eCollection 2017 Aug. J Glob Oncol. 2016. PMID: 28831436 Free PMC article. No abstract available.
-
Advancing perspectives on the off-label use of anticancer drugs: an updated classification and exploration of categories.Front Pharmacol. 2024 Jun 4;15:1374549. doi: 10.3389/fphar.2024.1374549. eCollection 2024. Front Pharmacol. 2024. PMID: 38898925 Free PMC article. Review.
-
Off-label use of immune checkpoint inhibitors for the treatment of solid tumors: analysis of a nationwide patient sample.J Cancer Res Clin Oncol. 2023 Sep;149(11):8655-8662. doi: 10.1007/s00432-023-04803-1. Epub 2023 Apr 28. J Cancer Res Clin Oncol. 2023. PMID: 37115271 Free PMC article.
-
Medical expenses of urban Chinese patients with stomach cancer during 2002-2011: a hospital-based multicenter retrospective study.BMC Cancer. 2018 Apr 17;18(1):435. doi: 10.1186/s12885-018-4357-y. BMC Cancer. 2018. PMID: 29665788 Free PMC article.
References
-
- American Academy of Pediatrics Uses of drugs not described in the package insert (off-label uses) Pediatrics. 2002;110(1):181–183. - PubMed
-
- American Society of Clinical Oncology Reimbursement for cancer treatment: coverage of off-label drug indications. J Clin Oncol. 2006;24(19):3206–3208. - PubMed
-
- Conroy S, Newman C, Gudka S. Unlicensed and off label drug use in acute lymphoblastic leukaemia and other malignancies in children. Ann Oncol. 2003;14(1):42–47. - PubMed
-
- Leveque D, Michallat AC, Schaller C, Ranc M. Off label drug use in adult patients treated by anticancer chemotherapy. Bulletin du cancer. 2005;92(5):498–500. - PubMed
LinkOut - more resources
Full Text Sources